摘要:目的：觀察厄貝沙坦治療非杓型高血壓患者降壓效果及其杓型血壓晝夜節(jié)律恢復(fù)情況,并觀察治療后血漿醛固酮水平的影響。方法:對杓型和非杓型兩組原發(fā)性高血壓患者分別給予150300 mg/d,觀察降壓效果及對血壓晝夜節(jié)律的影響,并監(jiān)測用藥前后血漿醛固酮水平的變化。結(jié)果:所有高血壓患者應(yīng)用厄貝沙坦治療前后收縮壓及舒張壓均有不同程度的下降,非杓型組夜間收縮壓及舒張壓的下降值與杓型相比有統(tǒng)計(jì)學(xué)差異,出現(xiàn)了明顯的晝夜節(jié)律,血漿醛固酮水平出現(xiàn)了明顯差異。結(jié)論:厄貝沙坦對非杓型高血壓患者有良好的降壓作用,并能恢復(fù)非杓型高血壓患者的晝夜節(jié)律,向杓型血壓變化。Abstract: Objective: To investigate the effect of blood pressure control and circadian variability of dipper blood pressure induced by irbesartan in patients with nondipper essential hypertension and to observe levels of aldosterone.after treatment.Methods:The patients were divided into dipper and nondipper groups. All patients were treated with irbesartan (150300 mg/d). The variability of circadian blood pressure were observed, and the levels of plasma aldosterone were monitored before and after treatment Results: After the treatment with irbesartan, the blood pressure in all patients were evidently reduced. The night blood pressure of the patient with nondipper essential hypertension had more significant improvement . The circadian variability was appeared. The levels of aldosterone had a significant difference between day and night. Conclusion:Irbesartan has significant effects for the patients with nondipper essential hypertension. It can induce a circadian variability and recover the dipper blood pressure from nondipper blood pressure.
摘要:目的: 比較咪達(dá)普利與培哚普利對原發(fā)性高血壓患者的的降壓效果和不良反應(yīng)。 方法 :將入選的60例1～2級高血壓病患者,隨機(jī)分為2組,咪達(dá)普利組,每日晨起口服咪達(dá)普利(5～10 mg,1次/d),培哚普利組,每日晨起口服培哚普利(4～8 mg,1次/d)。治療4周,觀察2組治療前、后的血壓,記錄不良反應(yīng)。 結(jié)果 :經(jīng)治療后咪達(dá)普利與培哚普利組血壓均明顯下降(Plt;0.05),組間差異無統(tǒng)計(jì)學(xué)意義(P＞0.05);總不良反應(yīng)發(fā)生率咪達(dá)普利組16.8%,培哚普利組20%,而咪達(dá)普利組的咳嗽發(fā)生率為6.8%,培哚普利組為16.8%。 結(jié)論 :咪達(dá)普利和培哚普利均能有效降壓,二者降壓效果相似,但咪達(dá)普利的咳嗽發(fā)生率較低。Abstract: Objective: To compare the antihypertensive efficacy and safety of imidapril versus peridopril in patients with essential hypertension. Methods : Selected 60 patients with mild to moderate essential hypertension, in which divided two groups by random.They were administered imidapril 5～10 mg once daily or and peridopril 4～8 mg once daily for 4 weeks. During the curative period of 4 weeks, the antihypertensive efficacy and adverse reaction were observed. Results :The blood pressure drecreased prominently in both groups after four weeks treament(Plt;0.05), but there was no significant difference in antihypertensive efficacy between the two groups(P＞0.05). The occurrence of the total adverse reaction in imidapril and peridopril groups was 16.8% and 20%, respectively, while the occurrence of the cough in two groups was 6.8% and 16.8%, respectively. Conclusion :Both imidapril and peridopril exert favourable and similar hepotensive effect, however the cough occurrence of imidapril is lower than that of peridopril.
本文旨在探討共濟(jì)失調(diào)毛細(xì)血管擴(kuò)張癥突變(ATM)基因單核苷酸多態(tài)性rs189037 C＞T與原發(fā)性高血壓(EH)之間的關(guān)系。我們采用病例對照研究法, 隨機(jī)選擇50歲以上的住院患者369例, 根據(jù)高血壓診斷標(biāo)準(zhǔn), 分為EH組(190例)和對照組(179例)。用聚合酶鏈?zhǔn)椒磻?yīng)-限制性片段長度多態(tài)性分析方法檢測ATM基因rs189037位點(diǎn)的基因型。在整個(gè)研究人群中, ATM基因rs189037的三種基因型CC、CT和TT分別占33.9%、48.0%和18.1%。三種基因型分布在EH組和對照組之間差異無統(tǒng)計(jì)學(xué)意義(P=0.619)。排除主要混雜因素以及性別和年齡分層分析后, 仍未發(fā)現(xiàn)ATM基因多態(tài)性rs189037與EH的發(fā)生相關(guān)(P＞0.05)。另外, TT型攜帶者中冠心病(CAD)發(fā)生風(fēng)險(xiǎn)明顯低于CC和CT基因型(OR=0.49, 95%CI=0.26~0.90, P=0.021)?？傊? ATM基因多態(tài)性rs189037與EH的發(fā)生沒有相關(guān)性, 但與CAD的發(fā)生密切相關(guān), TT基因型可能是CAD的保護(hù)因素。